oral glp 1 agonist for weight loss Revolutionary Treatment #Obesity… #UAE Approves an #Drug That Replaces Injections The UAE's Emirates Drug Establishment has approved orforglipron, commercially known as “Vondayo™,” an innovative oral treatment used for management ( Oral GLP-1 Weight Loss Medication

On average, volunteers in the retatrutide clinical trial who received the study drug rather than a placebo lost an average of 70.3 pounds over about a year-and-a-half, with more than 45% of participants losing more than 30% of their body weight

Both Eli Lilly and Novo Nordisk have been struggling to produce enough GLP-1 drugs to meet rising demand

Note that these outcomes were achieved in combination with diet and exercise, underlining the value of a holistic approach to weight loss and blood sugar management

Given this close association, a substantial number of obese individuals likely suffer from undiagnosed OSA, underscoring the need for proactive screening in obesity care

Instead of targeting just one problem, these drugs attack multiple problems simultaneously

Likewise, Benefits Magazine examined how employers are currently handling the demand for high-cost weight loss drugs